The stability of insulin-loaded polybutylcyanoacrylate nanoparticles in an oily medium and the hypoglycemic effect in diabetic rats

Yaoxue Xuebao

Volumn 40, Issue 1, 2005, Pages 57-64

  Hou, Zhen Qing ^a   Zhang, Zhen Xi ^a   Xu, Zheng Hong ^a   Zhang, Hong ^a   Tong, Ze Feng ^a   Leng, Yu Shan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Hypoglycemic effect; Insulin; Nanoparticles; Oral administration; Polybutylcyanoacrylate; Stability

Indexed keywords

ANTIDIABETIC AGENT; DRUG CARRIER; ENBUCRILATE; INSULIN; NANOMATERIAL; POLYMER; SOYBEAN OIL;

ANIMAL; ARTICLE; BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENBUCRILATE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NANOSTRUCTURES; PARTICLE SIZE; POLYMERS; RATS; RATS, WISTAR; SOYBEAN OIL;

EID: 33644669792     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats [J]. Int J Pharm, 2001,218(1):75-80.
2. Yang C, Hu L, Xu L, et al. Hypoglycemic effect of insulin-nanoparticles on diabetic rats [J]. J Fourth Mil Med Univ, 2001,22(6):696-700.
3. Yin Z, Lu B. Study on sustained release insulin nanoparticles for injection [J]. Chin Pharm J, 2000,31(3):349-352.
4. Sommerfeld P, Schroeder U, Sabel BA. Long-term stability of PBCA nanoparticle suspensions suggests clinical usefulness [J]. Int J Pharm, 1997,155(2): 201-207.
5. Sommerfeld P, Schroeder U, Sabel BA. Sterilization of unloaded polybutylcyanoacrylate nanoparticles [J]. Int J Pharm, 1998,164(1):113-118.
6. Scherer D, Kreuter J, Robinson JR. Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles [J]. Int J Pharm, 1994,101(2):165-168.
7. Lowe PJ, Temple GS. Calcitonin and insulin in isobutylcyanoacrylate nanoparticles: protection against proteases and effect on intestinal absorption in rats [J]. J Pharm Pharmacol, 1994,46(5):547-552.
8. Michel C, Aprahamian M, Defontaine L, et al. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanoparticles in diabetic rats [J]. J Pharm Pharmacol, 1991,43(1):1-5.
9. Damg C, Vranckx H, Balschmidt P, et al. Poly (alkylcyanoacrylate) nanospheres for oral administration of insulin [J]. J Pharm Sci, 1997,86(12):1403-1409.
10. Duan MX, Yue ZC, Ma H. Structure of insulin-encapsulated polyalkylcyanoacrylate nanoparticle [J]. Chin Pharm J, 1999,34(1):23-26.
11. Leonard F, Kuldarni RK, Brandes G, et al. Synthesis and degradation of poly (alkyl α-cyanoacrylates) [J]. J Appl Polym Sci, 1996,10(2):259-264.
12. Aprahamian M, Damgé C, Michel C. Transmucosal passage of polyalkylcyanoacylate nanocapsules as a new drug carrier in the small intestine [J]. Biol Cell, 1987, 61(1):69-76.
13. Lenaerts V, Couvreur P, Christiaens-Leyh D, et al. Degradation of poly (isobutylcyanoacrylate) nanoparticles [J]. Biomaterials, 1984,5(1):65-68.
14. Kitts AD. An evaluation of the multiple effects of the antioxidant Vitamins [J]. Trends Food Sci Technol, 1997,8(2):198-224.